Sarah L. Becker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sarah L. Becker has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Alex Gerardo Ortega-Loayza
Department of Dermatology, Oregon Health and Science University, Portland, USA
4 shared publications - Giovanni Traverso
Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA
2 shared publications - Katelyn Downey
Department of Dermatology, Oregon Health & Science University , Portland, OR
2 shared publications Aaron Lopes
Division of Gastroenterology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
1 shared publicationAdam J. Wentworth
Division of Gastroenterology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
1 shared publicationAhmed H. Badawi
Division of Dermatology, University of Kansas Medical Center, Kansas City, USA
1 shared publication
Latest Publications
- Open Access
- 19 June 2026
- Published by Elsevier in JID Innovations
- Vol. 6 (5) , 100500
Lesional pruritus in pyoderma gangrenosum: Present but not predominant
- 19 June 2026
- Published by Elsevier in JID Innovations
- Vol. 6 (5) , 100500
Open AccessLesional pruritus in pyoderma gangrenosum: Present but not predominant
- 5 March 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 195 (2) , 270-279
Minimum dataset for treatment effectiveness in pyoderma gangrenosum for an international registry: an international multidisciplinary eDelphi consensus
Background: Pyoderma gangrenosum (PG) is a rare, painful neutrophilic dermatosis with a profound impact on patient quality of life. Its management is hindered by a lack of approved therapies, limited clinical trials, and low-quality evidence. The rarity of the disease and funding constraints have impeded research progress and the development of standardized outcome measures. Patient data registries offer a promising solution to these challenges, providing essential infrastructure to improve the generation of evidence and clinical care. Objectives: To develop a consensus-based minimum dataset for an international treatment effectiveness registry for PG, informed by real-world clinical data. Methods: An initial list of candidate domain items was generated from a systematic literature review conducted according to a previously published protocol. An international, multistakeholder panel of 45 participants – including patients with PG, clinicians, researchers, methodologists and industry representatives – was convened from 97 invited experts. Through three rounds of modified Delphi surveys and a virtual consensus meeting, items were ranked using predefined criteria: ‘consensus in’ (≥ 70% scoring 7–9 and ≤ 15% scoring 1–3), ‘consensus out’ (≥ 70% scoring 1–3 and ≤ 15% scoring 7–9) and ‘no consensus’. A final verification survey confirmed inclusion if < 30% of participants voted ‘no’. Results: All 45 stakeholders completed all three Delphi rounds (0% dropout). Thirty-four (76%) participated in the consensus meeting, and 42 (93%) completed the final verification survey. Of 143 initial items across 24 domains, 118 items across 26 domains achieved consensus for inclusion in the minimum dataset. Conclusions: This international consensus establishes a standardized framework for collecting real-world data on PG. The resulting registry will serve as a critical resource for evaluating treatment effectiveness, understanding disease progression, and improving patient outcomes. It will also support future clinical trials, guideline development, quality improvement initiatives, and global patient recruitment efforts.
- 5 March 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 195 (2) , 270-279
Minimum dataset for treatment effectiveness in pyoderma gangrenosum for an international registry: an international multidisciplinary eDelphi consensus
Background: Pyoderma gangrenosum (PG) is a rare, painful neutrophilic dermatosis with a profound impact on patient quality of life. Its management is hindered by a lack of approved therapies, limited clinical trials, and low-quality evidence. The rarity of the disease and funding constraints have impeded research progress and the development of standardized outcome measures. Patient data registries offer a promising solution to these challenges, providing essential infrastructure to improve the generation of evidence and clinical care. Objectives: To develop a consensus-based minimum dataset for an international treatment effectiveness registry for PG, informed by real-world clinical data. Methods: An initial list of candidate domain items was generated from a systematic literature review conducted according to a previously published protocol. An international, multistakeholder panel of 45 participants – including patients with PG, clinicians, researchers, methodologists and industry representatives – was convened from 97 invited experts. Through three rounds of modified Delphi surveys and a virtual consensus meeting, items were ranked using predefined criteria: ‘consensus in’ (≥ 70% scoring 7–9 and ≤ 15% scoring 1–3), ‘consensus out’ (≥ 70% scoring 1–3 and ≤ 15% scoring 7–9) and ‘no consensus’. A final verification survey confirmed inclusion if < 30% of participants voted ‘no’. Results: All 45 stakeholders completed all three Delphi rounds (0% dropout). Thirty-four (76%) participated in the consensus meeting, and 42 (93%) completed the final verification survey. Of 143 initial items across 24 domains, 118 items across 26 domains achieved consensus for inclusion in the minimum dataset. Conclusions: This international consensus establishes a standardized framework for collecting real-world data on PG. The resulting registry will serve as a critical resource for evaluating treatment effectiveness, understanding disease progression, and improving patient outcomes. It will also support future clinical trials, guideline development, quality improvement initiatives, and global patient recruitment efforts.
- 22 September 2025
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 27 (1) , 145-147
Skin Ulcers Mimicking Pyoderma Gangrenosum: A Prospective Cohort Study
- 22 September 2025
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 27 (1) , 145-147
Skin Ulcers Mimicking Pyoderma Gangrenosum: A Prospective Cohort Study
- 28 March 2025
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 26 (4) , 511-523
Clinical Mimickers Misdiagnosed as Pyoderma Gangrenosum
Pyoderma gangrenosum (PG) is a rare, ulcerative, neutrophilic dermatosis that can be challenging to diagnose. Diagnosis of PG is clinical due to a lack of specific histopathologic, immunologic, or imaging findings associated with the disease, although several clinical frameworks exist to guide diagnosis. However, misdiagnosis of PG is frequent and leads to increased patient morbidity and mortality. This article highlights common mimickers of PG and offers clinical pearls to aid in accurate diagnosis with the goal of decreasing diagnostic delay and misdiagnosis and improving patient outcomes.
- 28 March 2025
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 26 (4) , 511-523
Clinical Mimickers Misdiagnosed as Pyoderma Gangrenosum
Pyoderma gangrenosum (PG) is a rare, ulcerative, neutrophilic dermatosis that can be challenging to diagnose. Diagnosis of PG is clinical due to a lack of specific histopathologic, immunologic, or imaging findings associated with the disease, although several clinical frameworks exist to guide diagnosis. However, misdiagnosis of PG is frequent and leads to increased patient morbidity and mortality. This article highlights common mimickers of PG and offers clinical pearls to aid in accurate diagnosis with the goal of decreasing diagnostic delay and misdiagnosis and improving patient outcomes.
- 25 February 2025
- Published by Wiley in Pediatric Dermatology
- Vol. 42 (5) , 1047-1050
Basiliximab for IL‐2‐Associated Inflammatory Disorder With Atopic Dermatitis
Options for pediatric patients with severe atopic dermatitis who do not respond to biologics remain limited. We report the case of a 10‐year‐old boy with severe, recalcitrant atopic dermatitis associated with episodic fever, joint pains, and elevated serum IL‐2R, which responded to basiliximab. To our knowledge, this is the first reported use of basiliximab for atopic dermatitis in a pediatric patient. This case highlights the potential for basiliximab as a therapy for severe cases of atopic dermatitis and the potential for precision medicine in dermatology.
- 25 February 2025
- Published by Wiley in Pediatric Dermatology
- Vol. 42 (5) , 1047-1050
Basiliximab for IL‐2‐Associated Inflammatory Disorder With Atopic Dermatitis
Options for pediatric patients with severe atopic dermatitis who do not respond to biologics remain limited. We report the case of a 10‐year‐old boy with severe, recalcitrant atopic dermatitis associated with episodic fever, joint pains, and elevated serum IL‐2R, which responded to basiliximab. To our knowledge, this is the first reported use of basiliximab for atopic dermatitis in a pediatric patient. This case highlights the potential for basiliximab as a therapy for severe cases of atopic dermatitis and the potential for precision medicine in dermatology.
- 9 November 2024
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 66 (1) , 27-31
Leishmaniasis masquerading as pyoderma gangrenosum in a non‐endemic area: A case report
Pyoderma gangrenosum (PG) can be difficult to diagnose, leading to diagnostic delay which affects patient outcomes and increases health care utilization. Among different scenarios of diagnostic delay, atypical infections can mimic PG. Here, we present a case of extensive cutaneous leishmaniasis initially misdiagnosed as the superficial granulomatous variant of PG and describe diagnostic clues to aid in differentiation.
- 9 November 2024
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 66 (1) , 27-31
Leishmaniasis masquerading as pyoderma gangrenosum in a non‐endemic area: A case report
Pyoderma gangrenosum (PG) can be difficult to diagnose, leading to diagnostic delay which affects patient outcomes and increases health care utilization. Among different scenarios of diagnostic delay, atypical infections can mimic PG. Here, we present a case of extensive cutaneous leishmaniasis initially misdiagnosed as the superficial granulomatous variant of PG and describe diagnostic clues to aid in differentiation.
- 1 February 2024
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 177 (2) , 257
Will It Ever Be Enough?
- 1 February 2024
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 177 (2) , 257
Will It Ever Be Enough?
- 29 June 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 14 (651) , eabl4135
Delivery of therapeutic carbon monoxide by gas-entrapping materials
Carbon monoxide (CO) has long been considered a toxic gas but is now a recognized bioactive gasotransmitter with potent immunomodulatory effects. Although inhaled CO is currently under investigation for use in patients with lung disease, this mode of administration can present clinical challenges. The capacity to deliver CO directly and safely to the gastrointestinal (GI) tract could transform the management of diseases affecting the GI mucosa such as inflammatory bowel disease or radiation injury. To address this unmet need, inspired by molecular gastronomy techniques, we have developed a family of gas-entrapping materials (GEMs) for delivery of CO to the GI tract. We show highly tunable and potent delivery of CO, achieving clinically relevant CO concentrations in vivo in rodent and swine models. To support the potential range of applications of foam GEMs, we evaluated the system in three distinct disease models. We show that a GEM containing CO dose-dependently reduced acetaminophen-induced hepatocellular injury, dampened colitis-associated inflammation and oxidative tissue injury, and mitigated radiation-induced gut epithelial damage in rodents. Collectively, foam GEMs have potential paradigm-shifting implications for the safe therapeutic use of CO across a range of indications.
- 29 June 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 14 (651) , eabl4135
Delivery of therapeutic carbon monoxide by gas-entrapping materials
Carbon monoxide (CO) has long been considered a toxic gas but is now a recognized bioactive gasotransmitter with potent immunomodulatory effects. Although inhaled CO is currently under investigation for use in patients with lung disease, this mode of administration can present clinical challenges. The capacity to deliver CO directly and safely to the gastrointestinal (GI) tract could transform the management of diseases affecting the GI mucosa such as inflammatory bowel disease or radiation injury. To address this unmet need, inspired by molecular gastronomy techniques, we have developed a family of gas-entrapping materials (GEMs) for delivery of CO to the GI tract. We show highly tunable and potent delivery of CO, achieving clinically relevant CO concentrations in vivo in rodent and swine models. To support the potential range of applications of foam GEMs, we evaluated the system in three distinct disease models. We show that a GEM containing CO dose-dependently reduced acetaminophen-induced hepatocellular injury, dampened colitis-associated inflammation and oxidative tissue injury, and mitigated radiation-induced gut epithelial damage in rodents. Collectively, foam GEMs have potential paradigm-shifting implications for the safe therapeutic use of CO across a range of indications.
- 1 October 2021
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 177, 113926
Devices for drug delivery in the gastrointestinal tract: A review of systems physically interacting with the mucosa for enhanced delivery
- 1 October 2021
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 177, 113926
Devices for drug delivery in the gastrointestinal tract: A review of systems physically interacting with the mucosa for enhanced delivery